UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 188

Sortiert nach

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating

Psychopharmacology, 2014-05, Vol.231 (10), p.2189-2197

2014

Volltextzugriff (PDF)

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo

The Journal of pharmacology and experimental therapeutics, 2012-05, Vol.341 (2), p.396

2012

Volltextzugriff (PDF)

Pharmacological disruption of mouse social approach behavior: Relevance to negative symptoms of schizophrenia

Behavioural brain research, 2013-09, Vol.252, p.405-414

2013

Volltextzugriff (PDF)

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

Neuropharmacology, 2007-02, Vol.52 (2), p.279-290

2007

Volltextzugriff (PDF)

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction

Behavioural brain research, 2010-09, Vol.212 (1), p.41-48

2010

Volltextzugriff (PDF)

Modulation of NMDA receptor function by inhibition of d-amino acid oxidase in rodent brain

Neuropharmacology, 2011-10, Vol.61 (5), p.1001-1015

2011

Volltextzugriff (PDF)

Reduction of brain kynurenic acid improves cognitive function

The Journal of neuroscience, 2014-08, Vol.34 (32), p.10592-10602

2014

Volltextzugriff (PDF)

Preclinical pharmacology of the alpha 4 beta 2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

Biochemical pharmacology, 2009-10, Vol.78 (7), p.813-824

2009

Volltextzugriff (PDF)

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

Journal of medicinal chemistry, 2018-02, Vol.61 (3), p.1001-1018

2018

Volltextzugriff (PDF)

Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect

European journal of pharmacology, 2009-03, Vol.605 (1), p.114-116

2009

Volltextzugriff (PDF)

Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

Biochemical pharmacology, 2009-10, Vol.78 (7), p.813-824

2009

Volltextzugriff (PDF)

Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists

Psychopharmacologia, 2010-06, Vol.210 (3), p.407-418

2010

Volltextzugriff (PDF)

Glycine transporter inhibition reverses ketamine-induced working memory deficits

Neuroreport, 2010-03, Vol.21 (5), p.390-394

2010

Volltextzugriff (PDF)

α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties

Behavioural pharmacology, 2011-08, Vol.22 (4), p.291

2011

Volltextzugriff (PDF)

Hyperphosphorylated Tau and Neurofilament and Cytoskeletal Disruptions in Mice Overexpressing Human p25, an Activator of cdk5

Proceedings of the National Academy of Sciences - PNAS, 2000-03, Vol.97 (6), p.2910-2915

2000

Volltextzugriff (PDF)

Tau protein phosphorylation as a therapeutic target in Alzheimer's disease

Current topics in medicinal chemistry, 2002-04, Vol.2 (4), p.395

2002

Volltextzugriff (PDF)

Cdk5 as a drug target for the treatment of Alzheimer's disease

Journal of molecular neuroscience, 2002-12, Vol.19 (3), p.267-273

2002

Volltextzugriff (PDF)

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants

Journal of medicinal chemistry, 1990-08, Vol.33 (8), p.2240-2254

1990

Volltextzugriff (PDF)

Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF-04447943

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S563-S564

2010

Volltextzugriff (PDF)

CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo

Stroke (1970), 2003, Vol.34 (1), p.171-176

2003

Volltextzugriff (PDF)

The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review

CNS drug reviews, 2003-03, Vol.9 (1), p.57-96

2003

Volltextzugriff (PDF)

3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents

Journal of medicinal chemistry, 1996-01, Vol.39 (1), p.143-148

1996

Volltextzugriff (PDF)

1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents

Journal of medicinal chemistry, 1991-06, Vol.34 (6), p.1860-1866

1991

Volltextzugriff (PDF)

5-cyano-1-[3-(N-methylpyrrolidin-2R-ylmethyl)indol-5-yl] benzimidazole (CP-161,242): A potent, centrally active 5-HT1D receptor agonist and benzodiazepine partial agonist

Bioorganic & medicinal chemistry letters, 1995-10, Vol.5 (20), p.2391-2396

1995

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(144)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(188)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(117)
Life Sciences & Biomedicine
(112)
Humans
(75)
Animals
(58)
Biological And Medical Sciences
(53)
Female
(51)
Male
(48)
Medical Sciences
(32)
Rats
(26)
Fundamental And Applied Biological Sciences. Psychology
(25)
Adult
(24)
Pharmacology & Pharmacy
(24)
Middle Aged
(22)
Neurosciences & Neurology
(21)
Neurosciences
(18)
Psychology. Psychoanalysis. Psychiatry
(15)
Aged
(14)
Mice
(14)
Pharmacology. Drug Treatments
(14)
Biochemistry & Molecular Biology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo

Pharmacological disruption of mouse social approach behavior: Relevance to negative symptoms of schizophrenia

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction

Modulation of NMDA receptor function by inhibition of d-amino acid oxidase in rodent brain

Reduction of brain kynurenic acid improves cognitive function

Preclinical pharmacology of the alpha 4 beta 2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate

Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect

Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

The Discovery and Characterization of the α‑Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Potentiator N‑{(3S,4S)‑4-[4-(5-Cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)

Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists

Glycine transporter inhibition reverses ketamine-induced working memory deficits

α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties

Hyperphosphorylated Tau and Neurofilament and Cytoskeletal Disruptions in Mice Overexpressing Human p25, an Activator of cdk5

Tau protein phosphorylation as a therapeutic target in Alzheimer's disease

Cdk5 as a drug target for the treatment of Alzheimer's disease

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants

Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF-04447943

CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo

The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review

3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents

1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents

5-cyano-1-[3-(N-methylpyrrolidin-2R-ylmethyl)indol-5-yl] benzimidazole (CP-161,242): A potent, centrally active 5-HT1D receptor agonist and benzodiazepine partial agonist

Suchergebnisse filtern